DRUG:AU:AU-BetaShares Global Healthcare Currency Hedged (AUD)

ETF | Others |

Last Closing

USD 8.43

Change

+0.04 (+0.48)%

Market Cap

USD 0.17B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
VAS:AU Vanguard Australian Shares

-0.68 (-0.66%)

USD 17.87B
IVV:AU iShares Core S&P 500 AUD

-0.24 (-0.38%)

USD 11.60B
VGS:AU Vanguard MSCI International Sh..

-0.42 (-0.30%)

USD 10.39B
QUAL:AU VanEck Vectors MSCI World ex A..

-0.18 (-0.30%)

USD 7.35B
IOZ:AU Ishares Core S&P/Asx 200

-0.20 (-0.60%)

USD 6.40B
STW:AU SPDR® S&P/ASX 200 Fund

-0.42 (-0.56%)

USD 5.57B
VTS:AU Vanguard US Total Market Share..

-1.67 (-0.36%)

USD 5.54B
NDQ:AU Betashares Nasdaq 100

-0.58 (-1.15%)

USD 5.22B
HNDQ:AU BetaShares NASDAQ 100 ETF - Cu..

-0.72 (-1.64%)

USD 4.86B
A200:AU BetaShares Australia 200

-0.91 (-0.66%)

USD 4.72B

ETFs Containing DRUG:AU

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.25% 93% A 71% C-
Dividend Return 0.35% 11% F 8% B-
Total Return 7.60% 94% A 72% C
Trailing 12 Months  
Capital Gain -1.52% 9% A- 48% F
Dividend Return 2.92% 41% F 33% F
Total Return 1.41% 10% F 47% F
Trailing 5 Years  
Capital Gain 34.24% 72% C 72% C
Dividend Return 11.65% 27% F 28% F
Total Return 45.89% 64% D 70% C-
Average Annual (5 Year Horizon)  
Capital Gain 6.78% 64% D 55% F
Dividend Return 8.53% 63% D 53% F
Total Return 1.75% 57% F 37% F
Risk Return Profile  
Volatility (Standard Deviation) 8.50% 65% D 92% A
Risk Adjusted Return 100.32% 89% A- 96% N/A
Market Capitalization 0.17B 33% F 65% D

Annual Financials (AUD)

Quarterly Financials (AUD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.